Cefcapene

Cefcapene
Clinical data
Trade names	Flomox
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	J01DD17 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name (6R,7R)-3-{[(Aminocarbonyl)oxy]methyl}-7-{(Z)-[2-(2-amino-4-thiazolyl)-1-oxo-2-pentenyl]amino}-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid;
CAS Number	135889-00-8 ;
PubChem CID	6436055;
ChemSpider	4940731 ;
UNII	4D5D3422MW;
KEGG	D07638 ;
ChEBI	CHEBI:131729 ;
ChEMBL	ChEMBL582912 ;
Chemical and physical data
Formula	C17H19N5O6S2
Molar mass	453.49 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=C/CC)\c3nc(sc3)N)COC(=O)N)C(=O)O;
	InChI InChI=1S/C17H19N5O6S2/c1-2-3-8(9-6-30-16(18)20-9)12(23)21-10-13(24)22-11(15(25)26)7(4-28-17(19)27)5-29-14(10)22/h3,6,10,14H,2,4-5H2,1H3,(H2,18,20)(H2,19,27)(H,21,23)(H,25,26)/b8-3-/t10-,14-/m1/s1 ; Key:HJJRIJDTIPFROI-NVKITGPLSA-N ;
	(what is this?) (verify)

Cefcapene (INN) is a third-generation cephalosporin antibiotic.

It was patented in 1985^[1] and approved for medical use in 1997^[1] in Japan, where it is sold under the Tradename Flomox by Shionogi & Co., Ltd.^[2] It is also approved and available as a generic in South Korea^[3] and China.^[4] It is known to cause severe hypocarnitinemia and associated serious hypoglycaemia, seizures, and encephalopathy in children.^[5]

References

1 2 Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 496. ISBN 9783527607495.
↑ "Pharmaceuticals and Medical Devices Safety Information No. 233" (PDF). Pharmaceuticals and Medical Devices Agency. March 2007. Retrieved 2026-08-06.
↑ "Cefcapene Pivoxil Hydrochloride Hydrate: Korea Drug Master Files (KDMF)". PharmaCompass. Retrieved 2026-08-06.
↑ Kim, Jisun (2024-09-11). "Yungjin Pharm Signs Antibiotic Export Contract Worth KRW 100 Billion with Chinese Pharmaceutical Company". Alpha Biz. Retrieved 2026-08-06.
↑ "Proper Use of Drugs Alert No. 17: Hypoglycemia Associated with Oral Pivoxil-Group Antibacterials in Children" (PDF). Pharmaceuticals and Medical Devices Agency. June 2026. Retrieved 2026-08-06.

This systemic antibiotic-related article is a stub. You can help Wikipedia by adding missing information.

[Fis2006-1] 1 2 Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 496. ISBN 9783527607495.

[2] "Pharmaceuticals and Medical Devices Safety Information No. 233" (PDF). Pharmaceuticals and Medical Devices Agency. March 2007. Retrieved 2026-08-06.

[3] "Cefcapene Pivoxil Hydrochloride Hydrate: Korea Drug Master Files (KDMF)". PharmaCompass. Retrieved 2026-08-06.

[4] Kim, Jisun (2024-09-11). "Yungjin Pharm Signs Antibiotic Export Contract Worth KRW 100 Billion with Chinese Pharmaceutical Company". Alpha Biz. Retrieved 2026-08-06.

[5] "Proper Use of Drugs Alert No. 17: Hypoglycemia Associated with Oral Pivoxil-Group Antibacterials in Children" (PDF). Pharmaceuticals and Medical Devices Agency. June 2026. Retrieved 2026-08-06.

[1]

[2]

[3]

[4]

[5]

This page was redesigned at the edge.

References